The PIONEER Comparative Effectiveness Study - Project 2
Key facts
- Who runs it
- University of Michigan
- Where
- Clinton Township, Detroit, Portland, Sylmar, and Torrance, United StatesSee the 6 sites
- Trial code
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 15 Oct 2026
- Expected to end
- Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Clinical pathway 1: Guidelines plus biomarkers
- Clinical guidelines only
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who cannot take part
- Current use of anticoagulant or antiplatelet therapy, including but not limited to: Warfarin, Factor Xa inhibitors (e.g., apixaban [Eliquis], rivaroxaban [Xarelto]), Clopidogrel, Ticagrelor
- Planned computed tomography (CT) imaging of the maxillofacial bones, chest, abdomen, or pelvis during the ED encounter AND clinicians do not intend to avoid brain CT imaging even if the biomarker test is negative
- Presentation >24 hours after injury, due to the declining diagnostic sensitivity of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) beyond this time window
Other criteria
- Inclusion
- Age ≥18 years at the time of the emergency department visit
- Presentation to a participating emergency department following a traumatic injury mechanism (motor vehicle collision, fall from height, assault, head injury/head trauma/head strike, struck by or against an object, facial injury or laceration, or other general trauma). Presentations may also include alcohol intoxication or syncope when associated with a suspected traumatic brain injury
- Evidence of potential head or brain injury, defined as (i) the head being struck by an object, (ii) the head striking a hard object or surface, (iii) exposure of the brain to significant acceleration/deceleration forces, or (iv) clinician documentation that the patient was evaluated for suspected traumatic brain injury
- Glasgow Coma Scale (GCS) score of 13-15 at presentation
- Presentation to the emergency department within 24 hours of injury
Where in United States
- Henry Ford Macomb (HFM)Clinton Township, United StatesContact: Jo-Ann RammalTaking people
- Henry Ford Hospital (HFH)Detroit, United StatesContact: Jo-Ann RammalTaking people
- Hillsboro Medical CenterPortland, United StatesContact: Maja Strusinska-ThayerTaking people
- Oregon Health & Science University (OHSU)Portland, United StatesContact: Maja Strusinska-ThayerTaking people
- UCLA-Olive View Medical CenterSylmar, United StatesContact: Yesenia PerezTaking people
- Harbor-UCLA Medical CenterTorrance, United StatesContact: Evelyn SantanaTaking people
About the trial
What the trial wants to find out
This is a pragmatic, open-label, multicenter, stepped-wedge, Type II hybrid effectiveness-implementation study. It is designed to evaluate both the comparative effectiveness and implementation feasibility of a biomarker-plus-clinical guidelines algorithm to reduce low-value brain computed tomography (CT) use in emergency department (ED) patients evaluated for suspected traumatic brain injury (TBI). The biomarkers are Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1), two brain-injury proteins cleared by the FDA to support brain CT imaging decisions after trauma. All six participating EDs will contribute baseline data for the first 6 months under usual care (clinical guidelines only). Beginning in month 7, two sites will transition to implementing the biomarker-guided algorithm. At month 13, two additional sites will implement the biomarker-guided approach, and the final two sites will transition at month 19. By the end of the 24-month rollout period, all sites will have implemented the biomarker-guided pathway.
The 2 groups in the trial
- Clinical Pathway 2: Clinical Guidelines OnlyExisting treatment, for comparison
Clinical Guidelines Only (Canadian CT Head Rule)
Treatment: Clinical guidelines only
- Clinical Pathway 1: Guidelines + BiomarkersTreatment being tested
Canadian CT Head Rule plus whole blood Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) measurement using the i-STAT.
Treatment: Clinical pathway 1: Guidelines plus biomarkers
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparing the Effectiveness of a Biomarker-plus-clinical Guidelines Algorithm Versus Clinical Guidelines Only for Safely Decreasing Brain Computed Tomography Utilization During Brain Injury Evaluations: The PIONEER Comparative Effectiveness Study
- Record updated
- 10 November 2026